Mindwalk Holdings Corp (HYFT)

$1.31 -0.02 (-1.14%)
Market Cap 60.96M
Revenue (ttm) 11.27M
Net Income (ttm) -10.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.71%
Debt to Equity Ratio 0.00
Volume 74,700
Avg Vol 184,022
Day's Range N/A - N/A
Shares Out 46.71M
Stochastic %K 29%
Beta 0.82
Analysts Sell
Price Target $4.33

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 800 620 4187
Address:
Industrious 823 Congress Ave, Suite 300, Austin, United States
Rbecca
Rbecca Sep. 13 at 2:01 PM
$HYFT
0 · Reply
JamesonGummies
JamesonGummies Sep. 13 at 2:00 AM
$HYFT
0 · Reply
TurningAProfit
TurningAProfit Sep. 12 at 2:00 PM
$HYFT
0 · Reply
Scam_Likely
Scam_Likely Sep. 12 at 2:41 AM
$HYFT the opportunity cost on this stock is about…1000%. Not even kidding. I am out and will start spreading the news of this slow dilution scam…fuck Bath.
0 · Reply
StockingGecks
StockingGecks Sep. 12 at 2:00 AM
$HYFT
0 · Reply
Ferg500
Ferg500 Sep. 11 at 2:00 PM
$HYFT
0 · Reply
Cozartarded
Cozartarded Sep. 11 at 2:00 AM
$HYFT
0 · Reply
ComeOnGuys
ComeOnGuys Sep. 10 at 2:29 PM
$HYFT can someone sell their shares so we can f-ing progress already
0 · Reply
LilCashOut
LilCashOut Sep. 10 at 2:00 PM
$HYFT
0 · Reply
Samuelstark
Samuelstark Sep. 10 at 12:18 PM
$HYFT
0 · Reply
Latest News on HYFT
MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 8:34 AM EDT - 3 days ago

MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026

Sep 8, 2026, 8:30 AM EDT - 5 days ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026

MindWalk Holdings Registration statement: Registration filing

Jul 28, 2026, 8:00 AM EDT - 6 weeks ago

MindWalk Holdings Registration statement: Registration filing

MindWalk showcases ReefIQ for AI drug discovery

2026-07-23T20:26:44.000Z - 7 weeks ago

MindWalk showcases ReefIQ for AI drug discovery

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

Jul 23, 2026, 4:02 PM EDT - 7 weeks ago

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

MindWalk Holdings Earnings Call Transcript: Q4 2026

Jul 22, 2026, 5:00 PM EDT - 7 weeks ago

MindWalk Holdings Earnings Call Transcript: Q4 2026

MindWalk Holdings Earnings release: Q4 2026

Jul 22, 2026, 5:00 PM EDT - 7 weeks ago

MindWalk Holdings Earnings release: Q4 2026

MindWalk Holdings Annual report: Q4 2026

Jul 22, 2026, 5:00 PM EDT - 7 weeks ago

MindWalk Holdings Annual report: Q4 2026

MindWalk Holdings Slides: Q4 2026

Jul 22, 2026, 5:00 PM EDT - 7 weeks ago

MindWalk Holdings Slides: Q4 2026

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

Jul 22, 2026, 4:54 PM EDT - 7 weeks ago

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

MindWalk files $250M mixed securities shelf

2026-07-13T20:10:59.000Z - 2 months ago

MindWalk files $250M mixed securities shelf

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

Jul 13, 2026, 9:00 AM EDT - 2 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026

MindWalk Holdings Registration statement: Registration filing

Jul 13, 2026, 8:00 AM EDT - 2 months ago

MindWalk Holdings Registration statement: Registration filing

MindWalk added to Russell 3000E Index

2026-07-06T12:41:35.000Z - 2 months ago

MindWalk added to Russell 3000E Index

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

Jul 6, 2026, 8:30 AM EDT - 2 months ago

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

MindWalk files European patent application for high-dimensional data structures

2026-07-01T12:16:34.000Z - 2 months ago

MindWalk files European patent application for high-dimensional data structures

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

Jul 1, 2026, 8:00 AM EDT - 2 months ago

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

Jun 12, 2026, 9:00 AM EDT - 3 months ago

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

ABSI

MindWalk launches ReefIQ context layer

2026-06-10T13:25:28.000Z - 3 months ago

MindWalk launches ReefIQ context layer

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

Jun 10, 2026, 9:16 AM EDT - 3 months ago

MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

MindWalk says preclinical dengue data support HYFT computational prediction

2026-06-02T11:33:59.000Z - 3 months ago

MindWalk says preclinical dengue data support HYFT computational prediction

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

Jun 2, 2026, 7:20 AM EDT - 3 months ago

MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

MindWalk announces launch of Pandemic Response Platform

2026-05-27T14:28:47.000Z - 3 months ago

MindWalk announces launch of Pandemic Response Platform

MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

May 27, 2026, 8:00 AM EDT - 3 months ago

MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

MindWalk identifies over 20 partner-owned drug programs reaching clinical trials

2026-05-18T12:45:01.000Z - 3 months ago

MindWalk identifies over 20 partner-owned drug programs reaching clinical trials

The Biology Came First.

May 18, 2026, 8:34 AM EDT - 3 months ago

The Biology Came First.

MindWalk initiated with a Buy at JonesResearch

2026-04-15T20:18:56.000Z - 5 months ago

MindWalk initiated with a Buy at JonesResearch

MindWalk Holdings Earnings Call Transcript: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 6 months ago

MindWalk Holdings Earnings Call Transcript: Q3 2026

MindWalk Holdings Earnings release: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 6 months ago

MindWalk Holdings Earnings release: Q3 2026

MindWalk Holdings Slides: Q3 2026

Mar 12, 2026, 10:30 AM EDT - 6 months ago

MindWalk Holdings Slides: Q3 2026

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Mar 12, 2026, 8:31 AM EDT - 6 months ago

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

MindWalk announces nanobody discovery platform

2026-03-06T21:05:43.000Z - 6 months ago

MindWalk announces nanobody discovery platform

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Mar 6, 2026, 4:01 PM EST - 6 months ago

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

Mar 2, 2026, 8:31 AM EST - 6 months ago

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

Jan 27, 2026, 12:01 AM EST - 7 months ago

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Jan 14, 2026, 8:00 AM EST - 8 months ago

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 12, 2026, 7:00 AM EST - 8 months ago

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk announces advance in influenza program

2026-01-11T19:45:16.000Z - 8 months ago

MindWalk announces advance in influenza program

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 9, 2026, 8:01 PM EST - 8 months ago

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Holdings Earnings Call Transcript: Q2 2026

Dec 15, 2025, 10:30 AM EST - 9 months ago

MindWalk Holdings Earnings Call Transcript: Q2 2026

MindWalk Holdings Earnings release: Q2 2026

Dec 15, 2025, 10:30 AM EST - 9 months ago

MindWalk Holdings Earnings release: Q2 2026

MindWalk Holdings Slides: Q2 2026

Dec 15, 2025, 10:30 AM EST - 9 months ago

MindWalk Holdings Slides: Q2 2026

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

Dec 15, 2025, 8:30 AM EST - 9 months ago

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

Dec 8, 2025, 8:30 AM EST - 9 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Nov 13, 2025, 9:00 AM EST - 10 months ago

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

MindWalk director Kamil Isaev resigns after failing to get majority vote

2025-10-21T13:15:32.000Z - 10 months ago

MindWalk director Kamil Isaev resigns after failing to get majority vote

MindWalk appoints R. Scott Areglado as Chief Financial Officer

2025-10-21T13:10:11.000Z - 10 months ago

MindWalk appoints R. Scott Areglado as Chief Financial Officer

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 21, 2025, 8:28 AM EDT - 10 months ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

MindWalk appoints Thomas Lynch as chief business officer

2025-10-15T11:05:12.000Z - 11 months ago

MindWalk appoints Thomas Lynch as chief business officer

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 15, 2025, 7:00 AM EDT - 11 months ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

MindWalk announces up to 2.3M share stock repurchase program

2025-10-09T11:05:22.000Z - 11 months ago

MindWalk announces up to 2.3M share stock repurchase program

MindWalk Announces Share Repurchase Program

Oct 9, 2025, 7:00 AM EDT - 11 months ago

MindWalk Announces Share Repurchase Program

MindWalk advances AI-designed GLP-1 therapeutics program

2025-09-22T11:25:07.000Z - 11 months ago

MindWalk advances AI-designed GLP-1 therapeutics program

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 22, 2025, 7:02 AM EDT - 11 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

MindWalk Holdings Earnings Call Transcript: Q1 2026

Sep 15, 2025, 10:30 AM EDT - 12 months ago

MindWalk Holdings Earnings Call Transcript: Q1 2026

MindWalk Holdings Earnings release: Q1 2026

Sep 15, 2025, 10:30 AM EDT - 12 months ago

MindWalk Holdings Earnings release: Q1 2026

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 15, 2025, 8:44 AM EDT - 12 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 3, 2025, 8:48 AM EDT - 1 year ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Sep 2, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 27, 2025, 8:22 AM EDT - 1 year ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 6, 2025, 8:00 AM EDT - 1 year ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Earnings Call Transcript: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings Call Transcript: Q4 2025

MindWalk Holdings Earnings release: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings release: Q4 2025

MindWalk Holdings Annual report: Q4 2025

Jul 29, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Annual report: Q4 2025

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 29, 2025, 8:28 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 24, 2025, 8:22 AM EDT - 1 year ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 21, 2025, 8:28 AM EDT - 1 year ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 16, 2025, 8:05 AM EDT - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 14, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 7, 2025, 9:00 AM EDT - 1 year ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jul 3, 2025, 8:19 AM EDT - 1 year ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 24, 2025, 7:02 AM EDT - 1 year ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 12, 2025, 8:01 AM EDT - 1 year ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

Jun 5, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 21, 2025, 8:49 AM EDT - 1 year ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 20, 2025, 8:28 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

May 12, 2025, 8:01 AM EDT - 1 year ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Apr 11, 2025, 8:40 AM EDT - 1 year ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

MindWalk Holdings Earnings Call Transcript: Q3 2025

Mar 28, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings Call Transcript: Q3 2025

MindWalk Holdings Earnings release: Q3 2025

Mar 28, 2025, 10:30 AM EDT - 1 year ago

MindWalk Holdings Earnings release: Q3 2025

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 28, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 13, 2025, 7:02 AM EDT - 1 year ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 11, 2025, 10:17 PM EDT - 1 year ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Mar 5, 2025, 8:01 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Rbecca
Rbecca Sep. 13 at 2:01 PM
$HYFT
0 · Reply
JamesonGummies
JamesonGummies Sep. 13 at 2:00 AM
$HYFT
0 · Reply
TurningAProfit
TurningAProfit Sep. 12 at 2:00 PM
$HYFT
0 · Reply
Scam_Likely
Scam_Likely Sep. 12 at 2:41 AM
$HYFT the opportunity cost on this stock is about…1000%. Not even kidding. I am out and will start spreading the news of this slow dilution scam…fuck Bath.
0 · Reply
StockingGecks
StockingGecks Sep. 12 at 2:00 AM
$HYFT
0 · Reply
Ferg500
Ferg500 Sep. 11 at 2:00 PM
$HYFT
0 · Reply
Cozartarded
Cozartarded Sep. 11 at 2:00 AM
$HYFT
0 · Reply
ComeOnGuys
ComeOnGuys Sep. 10 at 2:29 PM
$HYFT can someone sell their shares so we can f-ing progress already
0 · Reply
LilCashOut
LilCashOut Sep. 10 at 2:00 PM
$HYFT
0 · Reply
Samuelstark
Samuelstark Sep. 10 at 12:18 PM
$HYFT
0 · Reply
LuckyInvested
LuckyInvested Sep. 10 at 2:00 AM
$HYFT
0 · Reply
AlanBoyd123
AlanBoyd123 Sep. 9 at 2:00 PM
$HYFT
0 · Reply
CharliesStocks
CharliesStocks Sep. 9 at 2:00 AM
$HYFT
0 · Reply
Mother_Nature
Mother_Nature Sep. 8 at 2:00 PM
$HYFT
0 · Reply
Crabtrees
Crabtrees Sep. 8 at 2:00 AM
$HYFT
0 · Reply
RandomlySelected
RandomlySelected Sep. 7 at 2:00 PM
$HYFT
0 · Reply
OllieOverTheMoon
OllieOverTheMoon Sep. 7 at 1:59 AM
$HYFT
0 · Reply
WaltersWhite
WaltersWhite Sep. 6 at 1:59 PM
$HYFT
0 · Reply
Holmes99
Holmes99 Sep. 6 at 1:59 AM
$HYFT
0 · Reply
LondonLeaves9845
LondonLeaves9845 Sep. 5 at 1:59 PM
$HYFT
0 · Reply
RandomlySelected
RandomlySelected Sep. 5 at 1:59 AM
$HYFT
0 · Reply
Samuelstark
Samuelstark Sep. 4 at 2:00 PM
$HYFT
0 · Reply